Nivolumab plus ipilimumab:a potential regimen to rewrite treatment guidelines for ESCC  

作　　者：Yuejun Luo Nan Sun Jie He 

机构地区：[1]Department of Thoracic Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,100021 Beijing,China [2]State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第6期1875-1877,共3页信号转导与靶向治疗（英文）

基　　金：supported by the Fundamental Research Funds for the Central Universities(3332018070);the National Key Basic Research Development Plan(2018YFC1312105);the Beijing Natural Science Foundation(J20010).

摘　　要：The recent research published in The New England Journal of Medicine by Y.Doki et al.has reported the interim findings from the CheckMate 648,which is an international,multi-center,openlabel,and randomized phase 3 clinical trial to explore the role of dual immune checkpoints inhibitors combination for patients with advanced esophageal squamous cell carcinoma(ESCC)1.

关 键 词：REGIMEN ESOPHAGEAL 

分 类 号：R73[医药卫生—肿瘤]